PE
BCAX

Point72 Europe’s Bicara Therapeutics BCAX Stock Holding History

Point72 Europe’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.61K Buy
+292
New +$3.27K ﹤0.01% 606

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Europe's BCAX Position: Q3 2025 in Review

Point72 Europe opened a new position in Bicara Therapeutics (BCAX) in Q3 2025: 292 shares worth $4.61K. The stake represents ﹤0.01% of the portfolio and ranks #606 among its holdings.

114 funds tracked by Wall St. Rank hold BCAX as of Q3 2025.

  • Point72 Europe held 292 shares of Bicara Therapeutics worth $4.61K as of Q3 2025.
  • Bicara Therapeutics was a new Point72 Europe position in Q3 2025.
  • Bicara Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #606 holding.
  • 114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.